Monocyte-derived fibrocytes are found in wound healing environments [10]�C[12] and at tissue near a tumor edge [67]�C[69], both areas of increased serine Belinostat fda proteinase activity [38], [70]�C[73]. For instance, marapsin, a protease that also cleaves at arginine, is up-regulated in wound healing environments [70]. An intriguing possibility is that endogenous proteases, by generating tryptic fragments of albumin, help to potentiate fibrocyte differentiation in wounds and tissues near a tumor edge. Taken together, our results suggest that topical trypsin and trypsinized albumin potentiate wound healing at least in part by potentiating fibrocyte differentiation. While trypsin has been used in the treatment of burns and in wound dressings for more than 50 years, a mixture of albumin and trypsin may further speed wound healing, especially when applied to chronic wounds deficient in albumin [24]�C[27].

Acknowledgments We thank the staff at Beutel student health center for drawing blood from volunteers. Funding Statement This work was supported by National Institutes of Health (NIH) grant R01HL083029. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recent advances in our understanding of tumour biology have shown that, despite their great heterogeneity, cancer cells often remain dependent on a limited subset of genetic defects for their survival. The success of targeted therapies in CML, GIST and subgroups of NSCLC clearly indicates that even advanced disease needs the function of its founding oncogenes to grow and survive [1], [2].

This phenomenon, referred to as ��oncogene addiction��, offers the basis for targeted cancer therapy, which should ideally be devoid of unwanted side effects on normal cells [3]. Colorectal cancer (CRC) is characterized by well-known genetic defects: the great majority (70�C95%) of sporadic CRCs carry mutations that hyper-activate the Wnt pathway, ultimately leading to abnormal ��-catenin-dependent gene expression [4], [5], [6], [7]. These alterations occur early during tumour development [8] and likely represent addicting lesions for the tumor. Indeed, down-regulation of ��-catenin induces growth arrest and differentiation in CRC cells [9]. However, ��-catenin targeting fails to kill the cells [9], [10], [11].

This may be related to the fact that CRCs carry a variety of additional mutations which also appear to be relevant for survival. For instance, KRAS activating mutations are present in approximately 35�C50% of colon cancers [4], [6], [12], [13], [14]. If the full complement of Ras pathway members is taken into account, including NRAS, BRAF, NF1, RASSF1A and upstream receptor tyrosine kinases, then 60�C80% of the tumours show alteration of the pathway Anacetrapib [7], [15], [16].